-
1 Comment
Acceleron Pharma Inc is currently in a long term downtrend where the price is trading 2.7% below its 200 day moving average.
From a valuation standpoint, the stock is 93.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 82.1.
Acceleron Pharma Inc's total revenue sank by 34.2% to $26M since the same quarter in the previous year.
Its net income has dropped by 143.5% to $-57M since the same quarter in the previous year.
Finally, its free cash flow fell by 124.7% to $-39M since the same quarter in the previous year.
Based on the above factors, Acceleron Pharma Inc gets an overall score of 1/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| Sector | Real Estate |
| ISIN | NL0015000RT3 |
| Industry | Real Estate - Diversified |
| PE Ratio | nan |
|---|---|
| Target Price | nan |
| Market Cap | None |
| Dividend Yield | nan% |
| Beta | nan |
NEPI Rockcastle N.V. ("the Company", "NEPI Rockcastle", "the Group") is a public limited company domiciled in the Netherlands, having its registered office at Strawinskylaan 563, WTC Zuidas, Tower Ten, 5th Floor, 1077 XX Amsterdam, with registration number at the Dutch Chamber of Commerce 87488329. The Company's shares are listed on the Main Board of the JSE Limited (JSE), Euronext Amsterdam and A2X. NEPI Rockcastle is the premier owner and operator of shopping centres in Central and Eastern Europe ("CEE"). The Group benefits from a highly-skilled internal management team which combines asset management, development, investment, leasing and financial expertise.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0A3.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
